Atorvastatin Effect on COVID-19 Outcomes : A Propensity Score Matched Study on Hospitalized Patients
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: This study investigated the association of atorvastatin use on survival, need for intensive care unit (ICU) admission, and length of hospital stay (LOS) among COVID-19 inpatients.
MATERIALS AND METHODS: A retrospective study was conducted between March 20th, 2020, and March 18th, 2021, on patients with confirmed COVID-19 admitted to three hospitals in Tehran, Iran. The unadjusted and adjusted effects of atorvastatin on COVID-19 prognosis were investigated. Propensity score matching (PSM) was used to achieve a 1:1 balanced dataset with a caliper distance less than 0.1 and the nearest neighbor method without replacement.
RESULTS: Of 4322 COVID-19 patients, 2136 (49.42%) were treated with atorvastatin. After PSM, 1245 atorvastatin inpatients and 1245 controls were included with a median age of 62.0 (interquartile range [IQR]: 51.0, 76.0) and 63.0 (IQR: 51.0, 75.0) years, respectively. The standardized mean differences were less than 0.1 for all confounders, suggesting a good covariate balance. The use of atorvastatin was associated with decreased COVID-19 mortality (HR: 0.80; 95% CI: 0.68-0.95), whereas no relationship was found between atorvastatin and the need for ICU admission (HR: 1.21; 95% CI: 0.99-1.47). LOS was significantly higher in the atorvastatin cohort than controls (Atorvastatin vs. others: 7 [5, 11] vs. 6 [4, 10] days; p = 0.003). The survival rate was higher in combination therapy of atorvastatin plus enoxaparin than in those who received atorvastatin alone (p-value=0.001).
CONCLUSION: Atorvastatin may reduce the risk of COVID-19 in-hospital mortality and could be a beneficial option for an add-on therapy. Randomized trials are warranted to confirm the results of the current observational studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Current medicinal chemistry - (2024) vom: 21. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pourhoseingholi, Mohamad Amin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Atorvastatin; Enoxaparin |
|---|
| Anmerkungen: |
Date Revised 22.01.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2174/0109298673264305231025093939 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367421933 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367421933 | ||
| 003 | DE-627 | ||
| 005 | 20240122232234.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240122s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/0109298673264305231025093939 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1267.xml |
| 035 | |a (DE-627)NLM367421933 | ||
| 035 | |a (NLM)38251698 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pourhoseingholi, Mohamad Amin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Atorvastatin Effect on COVID-19 Outcomes |b A Propensity Score Matched Study on Hospitalized Patients |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 22.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: This study investigated the association of atorvastatin use on survival, need for intensive care unit (ICU) admission, and length of hospital stay (LOS) among COVID-19 inpatients | ||
| 520 | |a MATERIALS AND METHODS: A retrospective study was conducted between March 20th, 2020, and March 18th, 2021, on patients with confirmed COVID-19 admitted to three hospitals in Tehran, Iran. The unadjusted and adjusted effects of atorvastatin on COVID-19 prognosis were investigated. Propensity score matching (PSM) was used to achieve a 1:1 balanced dataset with a caliper distance less than 0.1 and the nearest neighbor method without replacement | ||
| 520 | |a RESULTS: Of 4322 COVID-19 patients, 2136 (49.42%) were treated with atorvastatin. After PSM, 1245 atorvastatin inpatients and 1245 controls were included with a median age of 62.0 (interquartile range [IQR]: 51.0, 76.0) and 63.0 (IQR: 51.0, 75.0) years, respectively. The standardized mean differences were less than 0.1 for all confounders, suggesting a good covariate balance. The use of atorvastatin was associated with decreased COVID-19 mortality (HR: 0.80; 95% CI: 0.68-0.95), whereas no relationship was found between atorvastatin and the need for ICU admission (HR: 1.21; 95% CI: 0.99-1.47). LOS was significantly higher in the atorvastatin cohort than controls (Atorvastatin vs. others: 7 [5, 11] vs. 6 [4, 10] days; p = 0.003). The survival rate was higher in combination therapy of atorvastatin plus enoxaparin than in those who received atorvastatin alone (p-value=0.001) | ||
| 520 | |a CONCLUSION: Atorvastatin may reduce the risk of COVID-19 in-hospital mortality and could be a beneficial option for an add-on therapy. Randomized trials are warranted to confirm the results of the current observational studies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Atorvastatin; Enoxaparin | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mortality; Propensity Score | |
| 700 | 1 | |a Yazdani, Omid |e verfasserin |4 aut | |
| 700 | 1 | |a Azizmohammad Looha, Mehdi |e verfasserin |4 aut | |
| 700 | 1 | |a Safavi-Naini, Seyed Amir Ahmad |e verfasserin |4 aut | |
| 700 | 1 | |a Esbati, Romina |e verfasserin |4 aut | |
| 700 | 1 | |a Ilkhani, Saba |e verfasserin |4 aut | |
| 700 | 1 | |a Taraghikhah, Nazanin |e verfasserin |4 aut | |
| 700 | 1 | |a Hatamabadi, Hamidreza |e verfasserin |4 aut | |
| 700 | 1 | |a Sadeghi, Amir |e verfasserin |4 aut | |
| 700 | 1 | |a Heidari, Kamran |e verfasserin |4 aut | |
| 700 | 1 | |a Namazi, Negarsadat |e verfasserin |4 aut | |
| 700 | 1 | |a Asadimanesh, Naghmeh |e verfasserin |4 aut | |
| 700 | 1 | |a Hatari, Saba |e verfasserin |4 aut | |
| 700 | 1 | |a Shahrokh, Shabnam |e verfasserin |4 aut | |
| 700 | 1 | |a Solhpour, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Jamialahmadi, Tannaz |e verfasserin |4 aut | |
| 700 | 1 | |a Santos, Raul D |e verfasserin |4 aut | |
| 700 | 1 | |a Sahebkar, Amirhossein |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current medicinal chemistry |d 1997 |g (2024) vom: 21. Jan. |w (DE-627)NLM093833857 |x 1875-533X |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:21 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/0109298673264305231025093939 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 21 |c 01 | ||